Future SLE therapies may also target the inhibition of other IFN receptor subunits, such as IFNLR1 (IL-28Rα) and IL-10R2; however, to the best of the authors’ knowledge, no clinical trials are ongoing. This evidence concerns the gene IFNLR1 and systemic lupus erythematosus.